STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who previously ...

The demand for intravitreal vascular endothelial growth factor (VEGF) inhibitor therapy is forecasted to increase by about 50% over the next 5 years in Denmark, due largely to an aging population, a ...

If you have wet age-related macular degeneration (wet AMD) or another disease of the retina, your doctor may recommend treatment with an anti-VEGF drug. VEGF, or vascular endothelial growth factor, is ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. One intravitreal injection of 4D-150 helped reduce the ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — When administering anti-VEGF treatments to patients with wet age-related macular degeneration, ...

Patients who received eye injections of anti-VEGF agents around the time of a stroke or myocardial infarction did not have an increased risk for mortality or major complications, and outcomes did not ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

Treatment strategies for diabetic macular oedema (DME) have evolved over the past decade, with focal laser therapy being largely replaced by intravitreal injections, an observational case series of ...

Eye injections are the only medication currently available to treat diabetes-related retinopathy. Modern eye injections are not painful and don’t cause many side effects. Diabetic retinopathy affects ...

Anti-VEGF drugs are associated with kidney injury for some patients, but no particular anti-VEGF has a stronger association than any others. The risk of kidney failure for people who receive ...